Surrey Heartlands

Joint Formulary & PAD

Venlafaxine - Menopausal disorders

You are here : Home > Formulary Search > Venlafaxine - Menopausal disorders

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Modified release tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
Guidelines BNF SPC
Un
Restrictions / Comments :
Important

Off-label use.

Documentation

Webpage
NICE NG23 menopause-diagnosis-and-management

PAD Profile

ChemicalSubstance :
Venlafaxine
Indication :
Menopausal disorders
Group Name :
Keywords :
Menopause, hot sweats, hot flushes, flushing, vasomotor symptoms, menopausal symptoms,
Brand Names Include :
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Menopausal disorders
Supporting Documents :
1

Other Indications

Below are listed other indications that Venlafaxine is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Menopausal disorders.

Committee Recommendations (2)

14 May 25 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC approved a change in Traffic Light Status from Blue to Green while reviewing drugs for inclusion on the Surrey Heartlands Joint Formulary.

It was agreed that GPs would initiate non-hormonal treatments for menopausal symptoms in accordance with CKS guidelines and NICE NG23: Menopause: identification and management

06 May 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee updated their recommendations in line with NICE guidance NG23 Menopause diagnosis and management in May 2020.

Venlafaxine is recommended for menopausal symptoms and a BLUE (with no information sheet) traffic light status has been agreed. Please refer to the Menopause -NG23 briefing paper attached below for further information (Page 13/14). SNRIs should not be routinely offered as a first line treatment for vasomotor symptoms.